Sari Fishman
CIK: 0002116402
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
CANF
Can-Fite BioPharma Ltd.
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Fishman Sari
Fishman Sari (SEC CIK 0002116402) files insider reports with the SEC as VP Business Development of Can-Fite BioPharma Ltd. (CANF).
Signal8 holds 1 ownership filing by Fishman Sari, a Form 3, filed on Mar 18, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Fishman Sari's filings is in RAMAT GAN.
Other insiders filing for Can-Fite BioPharma Ltd. (CANF)
- Farbstein Motti, CEO, CFO and COO
- Fishman Pnina, Chief Scientific Officer
- Tamir Ilan, Director
- Regev Guy, Director
- Bornstein Yoseph, Director
- Sartani Abraham, Director